During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...

Learn how new research and clinical trials at Memorial Sloan Kettering Cancer Center (MSK) have helped 32-year-old Giancarlo ...

George Dudnik was diagnosed with stage four lung cancer in November – and was told he would die from it despite being ...

Second, AUGTYRO in ROS1 positive non-small cell lung cancer ... Nevertheless, we are going to test the combination with carbo and then we will have to select the dose for ZL-1310 with that ...

The ROS1 mutation is similar to the ALK mutation ... The results of a genetic test can help your doctor find a targeted therapy that’s more likely to work against your specific type of cancer.

However, a doctor may still prescribe if you have ROS1-positive lung cancer ... Clinical trials are a way to test the safety and effectiveness of experimental therapies that aren’t yet approved ...

These biomarkers are EGFR, ALK, ROS1, BRAF, KRAS, MET, HER2, RET, and NTRK. Your doctor will choose treatments that are most likely to work based on the mutations they find in your NGS test results.

Dunn’s test was applied for nonparametric comparisons among multiple ... The SEER database does not present molecular markers, including EGFR, ALK, and ROS1, which are critical in guiding the ...

ROS1 is a rare mutation found in fewer than 2% of NSCLC cases. Currently there is a lack of treatments for ROS1-positive NSCLC, especially for people whose lung cancer has spread to the brain.